US biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Monday that it has completed the transfer of the Investigational New Drug application (IND) for its breast cancer vaccine from Cleveland Clinic.

Anixa is now the trial sponsor for future development of the vaccine.

The company said that, with enrolment completed and encouraging immune response and safety data observed in the Phase 1 trial, it intends to advance the vaccine into a Phase 2 clinical trial and has assumed full sponsorship of the IND. Anixa is planning to use multiple clinical sites, including Cleveland Clinic, for the Phase 2 and other clinical trials.